Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis
To assess the effectiveness and safety of tumor treating fields (TTF) in conjunction with chemotherapy compared to chemotherapy alone in glioblastoma patients, including both newly diagnosed and recurrent cases.
Key Findings:
TTF combined with chemotherapy significantly extended progression-free survival (PFS) (HR = 0.62, 95% CI: 0.55–0.69, P < 0.0001) and overall survival (OS) (HR = 0.63, 95% CI: 0.56–0.72, P < 0.0001) in glioblastoma patients.
No significant difference in systemic adverse events (OR = 1.10, 95% CI: 0.79–1.53, P = 0.571) between TTF and chemotherapy alone groups.
Increased incidence of skin irritation in the TTF cohort (OR = 12.87, 95% CI: 7.47–22.18, P < 0.0001).
Interpretation:
The combination of TTF and chemotherapy offers a promising therapeutic approach for glioblastoma, enhancing survival rates without increasing systemic toxicity compared to standard treatments.
Limitations:
Variability in study designs and patient populations may affect the generalizability of the results.
Potential bias in selected trials could influence the outcomes.
Conclusion:
TTF in conjunction with chemotherapy markedly improves survival rates in glioblastoma patients, indicating its efficacy and safety compared to existing treatment standards.
